Details of Disease

General Information of Disease (ID: DISAVQI3)

• Disease Name: Severe asthma
• Synonyms: severe asthma attack; asthma with status asthmaticus
• Disease Class: CA23: Asthma
• Definition: An acute exacerbation of asthma, characterized by inadequate response to initial bronchodilators.
• Disease Hierarchy:
  DISW9QNS: Asthma
  DISAVQI3: Severe asthma
• ICD Code:
  ICD-11: ICD-11: CA23
  ICD-10: ICD-10: J45, J45.8
  ICD-9: ICD-9: 493
  Expand ICD-9: 493
• Disease Identifiers:
  MONDO ID: MONDO_0004766
  MESH ID: D013224
  UMLS CUI: C0038218
  MedGen ID: 11584
  HPO ID: HP:0012653
  SNOMED CT ID: 708090002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 16 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aminophylline	DML2NIB	Approved	Small molecular drug	[1]
Betamethasone	DMAHJEF	Approved	Small molecular drug	[2]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[3]
Epinephrine	DM3KJBC	Approved	Small molecular drug	[4]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[5]
Mepolizumab	DMW2GEJ	Approved	Monoclonal antibody	[6]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[7]
Norepinephrine	DMOUC09	Approved	Small molecular drug	[8]
Pirbuterol	DMI5678	Approved	Small molecular drug	[9]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[10]
Reslizumab	DM0AUCH	Approved	Monoclonal antibody	[11]
Salbutamol	DMN9CWF	Approved	Small molecular drug	[12]
Terbutaline	DMD4381	Approved	Small molecular drug	[13]
Tezepelumab	DM9R5J6	Approved	Antibody	[14]
Theophylline	DMRJFN9	Approved	Small molecular drug	[15]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[16]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lebrikizumab	DMQP0X5	Phase 3	Monoclonal antibody	[17]
KB-003	DM74KIM	Phase 2	Antibody	[18]
KN-002	DMK8FHB	Phase 1	Small molecule	[19]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Aminophylline FDA Label
• [2] Betamethasone FDA Label
• [3] Cortisone acetate FDA Label
• [4] Epinephrine FDA Label
• [5] Hydrocortisone FDA Label
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7685).
• [7] Methylprednisolone FDA Label
• [8] Norepinephrine FDA Label
• [9] Pirbuterol FDA Label
• [10] Prednisolone FDA Label
• [11] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [12] Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial. Pediatr Pulmonol. 2019 Apr;54(4):372-377.
• [13] Terbutaline FDA Label
• [14] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761224.
• [15] Theophylline FDA Label
• [16] Triamcinolone FDA Label
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7684).
• [18] ClinicalTrials.gov (NCT00995449) Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT05006521) Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, PK, and PD of Single Ascending Doses of KN-002 in Healthy Subjects and Multiple Ascending Doses of KN-002 in Subjects With Mild Asthma, Moderate-Severe Asthma and COPD. U.S.National Institutes of Health.